Skip to content
value.today

Sunesis Pharmaceuticals Inc.

Formerly MOSAIC PHARMACEUTICALS INC

Total raised
$39 M
2 rounds on record
Latest round
$29 M
Jun 2010
First round on record
Apr 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Sunesis Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2010$29 MNo. 2$10 to $50 million

Sunesis Pharmaceuticals Inc.: Raise no. 2, Jun 2010

Investors in this round

18 investors had bought by the notice of Jul 14, 2010: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$29 M of $29 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
$1,197,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel N., Jr. Swisher · Executive Officer, Director
  • Eric H. Bjerkholt · Executive Officer
  • Steven H. Ketchum · Executive Officer
  • David C. Stump · Director
  • Dayton K. Misfeldt · Director
  • Ed K. Hurwitz · Director
  • Helen Susan Kim · Director
  • Homer L. Pearce · Director
  • James W. Young · Director
  • Matthew K. Fust · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Jefferies & Company, Inc. (CRD 2347) · New York, New YorkSold in CA, CT, DC, FL, MA, MD, NC, NJ, NY, PA, WA

Remarks in the notice

  • On fees: “Placement agent fees paid in this offering to Recipient listed in Item 12.”
  • On the use of proceeds: “Proceeds from private placement are to be used for working capital and other general corporate purposes.”

Signed by Eric Bjerkholt, SVP, Corp.Dev.& Finance, CFO & Corp. Secretary. Source: SEC Form D, newest notice filed Jul 14, 2010. Read the notice at the SEC.

equitySEC
Apr 2009$10 MNo. 1$10 to $50 million

Sunesis Pharmaceuticals Inc.: Raise no. 1, Apr 2009

Investors in this round

18 investors had bought by the notice of Apr 17, 2009: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $15 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
$588,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • Daniel N., Jr. Swisher · Executive Officer, Director
  • Eric H. Bjerholt · Executive Officer
  • Steven B. Ketchum · Executive Officer
  • David C. Stump · Director
  • Dayton Misfeldt · Director
  • Ed Hurwitz · Director
  • Homer L. Pearce · Director
  • James W. Young · Director
  • Matthew K. Fust · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Jefferies & Company, Inc. (CRD 2347) · New York, NySold in no state named

Remarks in the notice

  • On fees: “*Placement Agent Fees paid in this offering to Recipient listed in Item 12.”
  • On the amounts: “Private placement of the sale up to $15.0 million of units consisting of Series A Preferred Stock and warrants to purchase common stock.”
  • On the use of proceeds: “Proceeds from the private placement are to be used for working capital and other general corporate purposes.”

Signed by Eric Bjerkholt, SVP Corporate Development & Finance, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 17, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Sunesis Pharmaceuticals Inc. had revenue of up to $1 million when it filed its newest notice of a funding round (Jul 2010).

    SEC Form D (revenue range) · Jul 2010

  • Revenue range over time, as stated in its notices: revenue between $1 million and $5 million in 2009; revenue of up to $1 million in 2010.

    SEC Form D (revenue range) · Jul 2010

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2010

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Sunesis Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 18 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Sunesis Pharmaceuticals Inc.
NameRoleNamed in
Daniel N., Jr. SwisherExecutive officerJul 2010
Eric H. BjerkholtExecutive officerJul 2010
Steven H. KetchumExecutive officerJul 2010
Eric H. BjerholtExecutive officerApr 2009
Steven B. KetchumExecutive officerApr 2009
Daniel N., Jr. SwisherDirectorJul 2010
David C. StumpDirectorJul 2010
Dayton K. MisfeldtDirectorJul 2010
Ed K. HurwitzDirectorJul 2010
Helen Susan KimDirectorJul 2010
Homer L. PearceDirectorJul 2010
James W. YoungDirectorJul 2010
Matthew K. FustDirectorJul 2010
Dayton MisfeldtDirectorApr 2009
Ed HurwitzDirectorApr 2009